ArticleJournal of the American Heart Association2015
Identifying Individuals at Risk for Cardiovascular Events Across the Spectrum of Blood Pressure Levels.
Article in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes.Journal of human hypertension · 2023Trial
- Trial
- Flexible wearable medical devices: from material innovations and data processing to intelligent healthcare applications.Journal of advanced research · 2026Review
- How the Latest Guidelines Are Changing the Diagnostic and Therapeutic Landscape of Arterial Hypertension.Journal of clinical medicine · 2025Article
- Tracking of blood pressure levels from childhood.Pediatric nephrology (Berlin, Germany) · 2025Review
- Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study.Medicina (Kaunas, Lithuania) · 2023Observational
- Systolic Blood Pressure and Cardiovascular Risk: Straightening the Evidence.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Hypertension (Blood Pressure) and Lifetime Risk of Target Organ Damage.Current hypertension reports · 2020Review
- Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study.Lancet (London, England) · 2019Article
- Blood pressure: at what level is treatment worthwhile?Australian prescriber · 2019Review
- Hypertension.Annals of internal medicine · 2019Article
- Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment.Journal of the American College of Cardiology · 2017Review
- Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention.Hypertension (Dallas, Tex. : 1979) · 2017Article
- Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy.Circulation · 2017Article
- Mango Supplementation Has No Effects on Inflammatory Mediators in Obese Adults.Nutrition and metabolic insights · 2017Article
- The Case for Low Blood Pressure Targets.American journal of hypertension · 2017Review
- Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment.JAMA cardiology · 2016Article
- Intensive lowering of blood pressure: Should we SPRINT?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016Article
- Targeting Multivariable Risks: An Opportunity for Population High Blood Pressure Control.Journal of the American Heart Association · 2015Article
- De-risking primary prevention: role of imaging.Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe determined the proportion of atherosclerotic cardiovascular disease (ASCVD) events that occur across the spectrum of systolic blood pressure (SBP) and assessed whether multivariable risk assessment can identify persons who experience ASCVD events at all levels of SBP, including those with goal levels. METHODS AND
resultsParticipants aged 45 to 64 years from the Framingham Offspring and Atherosclerosis Risk in Communities studies were stratified based on treated and untreated SBP levels (<120, 120 to 129, 130 to 139, 140 to 149, 150 to 159, ≥160 mm Hg). We determined the number of excess ASCVD events in each SBP stratum by calculating the difference between observed and expected events (ASCVD event rate in untreated SBP <120 mm Hg was used as the reference). We categorized participants into 10-year ASCVD risk groups using the Pooled Cohort risk equations. There were 18 898 participants (78% white; 22% black) who were followed for 10 years. We estimated 427 excess ASCVD events, of which 56% (109 of 197) and 50% (115 of 230), respectively, occurred among untreated and treated participants with elevated SBP who were not recommended for antihypertensive therapy. Among untreated participants, 10-year ASCVD risk ≥7.5% identified 64% of those who experienced an ASCVD at 10 years and 30% of those who did not. Multivariable risk assessment was less useful in baseline-treated participants.
conclusionsHalf of excess ASCVD events occurred in persons with elevated SBP who were not currently recommended for antihypertensive therapy. Multivariable risk assessment may help identify those likely to benefit from further risk-reducing therapies. These findings support consideration of multivariable risk in guiding prevention across the spectrum of SBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.